Quarterly report pursuant to Section 13 or 15(d)

Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.22.1
Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2021
Mar. 31, 2022
Dec. 31, 2021
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Net sales   $ 290,376   $ 243,552 $ 817,371 $ 672,004
Operating income   90,447   68,626 216,017 168,714
Costs recognized on sale of acquired inventory         (1,596) (91)
Impact of partially owned consolidated subsidiaries(1)   595   380 9,343 509
Eminence impairment         (18,715) 0
Restructuring costs     $ (242)      
Corporate general, selling, and administrative expenses   (89,269)   (82,596) (276,137) (238,310)
Diagnostics and Genomics [Member]            
Restructuring costs $ (1,200) 300 $ (500)      
Operating Segments [Member]            
Operating income   116,155   99,400 317,879 266,985
Costs recognized on sale of acquired inventory       (68) (1,596) (91)
Amortization of acquisition related intangible assets   (18,173)   (15,222) (54,942) (45,750)
Impact of partially owned consolidated subsidiaries(1)   (892)   (699) (3,446) (906)
Acquisition related expenses   3,710   (1,731) 19,328 (6,289)
Eminence impairment         (18,715)  
Stock based compensation, inclusive of employer taxes   (9,056)   (11,968) (37,731) (41,525)
Restructuring costs   291     (1,638) (142)
Operating Segments [Member] | Protein Sciences [Member]            
Net sales   213,176   185,623 615,332 512,248
Operating income   96,750   88,983 280,131 239,788
Operating Segments [Member] | Diagnostics and Genomics [Member]            
Net sales   77,679   58,093 203,191 160,687
Operating income   19,405   10,417 37,748 27,197
Intersegment Eliminations [Member]            
Net sales   (479)   (164) (1,152) (931)
Corporate, Non-Segment [Member]            
Corporate general, selling, and administrative expenses   $ (1,588)   $ (1,086) $ (3,122) $ (3,568)